Results 131 to 140 of about 4,025 (222)

Successful Tepotinib Rechallenge after Tepotinib-induced Adverse Events Following Pembrolizumab Failure in a Case of Non-small Cell Lung Carcinoma with MET Exon 14 Skipping. [PDF]

Intern Med
Yasuda Y, Hattori Y, Satouchi M.
europepmc   +1 more source

Functionally substituted arylhydrazones as building blocks in heterocyclic synthesis: routes to pyridazines and pyridazinoquinazolines

ARKIVOC, 2006
Said Ahmed Soliman Ghozlan, Ismail Abdelshafy Abdelhamid, Mohamed Hilmy Elnagdi   +2 more
doaj   +1 more source

Deuteration of Six-Membered N-Heteroarenes: Chemistry and Applications. [PDF]

Chemistry
Raju L, Tiz DB, Iles A, Košmrlj J, Jansen-van Vuuren RD.   +4 more
europepmc   +1 more source

Pharmacokinetics of dolutegravir, tenofovir and lamivudine during venous-venous extracorporeal membrane oxygenation (VV-ECMO): A case report. [PDF]

Br J Clin Pharmacol
Zwart TC, Leegwater E, Ottens TH, Schippers EF, Wilms EB, Burger DM, van Nieuwkoop C, Bosma LBE.   +7 more
europepmc   +1 more source

Ponatinib confers adult human cardiomyocyte toxicity via inhibition of AKT signaling. [PDF]

Physiol Rep
Guo L, Rao R, Liu H, Zhou B.
europepmc   +1 more source

Rearrangement Cascade Initiated by Nucleophilic Benzyne Attack on 3,6-Di(2-pyridyl)-1,2-diazines. [PDF]

ACS Org Inorg Au
Schöntag J, Hettiger T, Roberts W, Scheele M, Ströbele M, Bettinger HF.   +5 more
europepmc   +1 more source

The global patent landscape of the drugs for treating Alzheimer's disease from 2014-2023. [PDF]

BMC Neurol
Xu Y, Gao Y.
europepmc   +1 more source

A Ponatinib-Associated Transcriptomic Signature: Implications for Cardiovascular Toxicity. [PDF]

Int J Mol Sci
Kong J, Jang J, Kong JH, Lee T.
europepmc   +1 more source

The first practical approach to new pyrimido[4,5-d]pyridazines: novel chemoselective and regioselective reactions

ARKIVOC, 2013
Bahador Karami, Sedigheh Akrami, Saeed Khodabakhshi, S. Setareh Rahmatzadeh   +3 more
doaj   +1 more source

Challenges and Limitations of Sequential MET-TKI Therapy in METex14- Positive NSCLC With a Focus on Non-ILD Toxicities: A Case Report. [PDF]

Cancer Rep (Hoboken)
Nigi A, Kumasa T, Iwamoto K, Itani H, Kondou S, Uraki J.   +5 more
europepmc   +1 more source